Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

Dedov, Ivan I.; Иванович, Дедов Иван; Калашникова, Марина Федоровна; Федоровна, Калашникова Марина; Коломиец, В. М.; Юрьевич, Белоусов Дмитрий; Kolbin, A. S.; Сергеевич, Колбин Алексей; Rafalskiy, Vladimir V.; Витальевич, Рафальский Владимир; Cheberdа, А. E.; Евгеньевич, Чеберда Алексей; Kantemirova, Mariya A.; Алексеевна, Кантемирова Мария; Zakiev, Vadim D.; Дмитриевич, Закиев Вадим; Fadeyev, Valentin V.; Викторович, Фадеев Валентин

doi:10.14341/dm9278

Cited by 21 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the National Register (Gosregistr) of DM, there were 3,988,718 patients suffering from type 2 diabetes mellitus (T2DM) in Russia from 2000 to 2015. However, the results of the National epidemiological observational cross-sectional study (NATION study) (2016) indicate that only about 50% of DM patients are diagnosed [1]. According to World Health Organization (WHO) data, the number of patients with DM was 174 million individuals worldwide in 2015, reaching 236 million a year later [2].…”

Section: Introductionmentioning

confidence: 99%

Modification of Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome

Galstyan

Недосугова

Мартиросян

et al. 2019

Biology

View full text Add to dashboard Cite

Background: This study involves the investigation of spontaneous and induced secretion of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) and the anti-inflammatory chemokine C-C motif chemokine ligand 18 (CCL18) by monocytes isolated from blood of patients with long-term type 2 diabetes mellitus (T2DM), both with or without foot ulcers. Methods: A total of 121 patients with T2DM (79 without diabetic foot syndrome (DFS) and 42 patients with DFS) were included. Cluster of Differentiation 14 (CD14+) monocytes were isolated from patients’ blood and stimulated by interferon-γ (IFN-γ) and interleukin-4 (IL-4) for induction of pro- and anti-inflammatory monocyte activation, respectively. The concentrations of TNF-α and CCL18 in the culture medium were measured using ELISA on day 1 and day 6 after cell stimulation. Results: We found a correlation between glycated hemoglobin (HbA1c) and stimulated secretion levels of TNF-α (r = 0.726, p = 0.027) and CCL18 (r = –0.949, p = 0.051) in patients with DFS. There was an increase of pro- and anti-inflammatory activation of monocytes in all patients with different durations of DFS (p < 0.05). However, no stimulation of anti-inflammatory activation was detected in patients with DFS lasting more than 6 months (p = 0.033). Conclusions: Our study showed an increase in pro-inflammatory secretion and a decrease in anti-inflammatory secretion by monocytes isolated from blood of patients with T2DM depending on HbA1c levels and duration of the inflammatory process. These findings allow us to assume that monocytes isolated from T2DM patients are characterized by a biased ability to respond towards pro-inflammatory stimulation, contributing to the chronic wound process.

show abstract

Section: Introductionmentioning

confidence: 99%

Modification of Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome

Galstyan

Недосугова

Мартиросян

et al. 2019

Biology

View full text Add to dashboard Cite

show abstract

“…In the Russian Federation, the total direct costs of the treatment for T2DM, its complications, and comorbidities per patient per year were more than 2,700 US dollars, the direct nonmedical costs were more than 600 US dollars, and the indirect costs were almost 3,900 US dollars (33). Thus, the total cost of T2DM treatment per patient per year was almost 7,300 US dollars.…”

Section: Discussionmentioning

confidence: 99%

Assessing the Effectiveness of Type 2 Diabetes Screening in the Republic of Uzbekistan

Alieva

Alimov

Khaydarova

et al. 2022

Int J Endocrinol Metab

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus (T2DM) screening should be performed continuously at the primary care level in order to prevent disabling complications. Due to the high prevalence of undiagnosed T2DM in the Republic of Uzbekistan, a decision was made to implement a nationwide screening program aimed at T2DM patients. Objectives: The current study, taking into account the limited resources of Uzbekistan's health care system, aimed to offer the most effective, simple, and economical option required for the actual implementation of regular T2DM screening in the country’s primary care. Methods: The screening was conducted from December 2018 to March 2019. There were four different scenarios, which differed in terms of eligibility criteria and the methodology adopted for detecting dysglycemia. Results: A total of 2,430 patients were examined in four months. The T2DM diagnosis was established by an endocrinologist in 9.3% of the cases with one eligibility criterion and 15.9% of the cases with three eligibility criteria. The diagnosis of T2DM was established by an endocrinologist in 11.7% of the cases with HbA1c screening and 13.5% of the cases with glucose screening. Conclusions: The screening was feasible in Uzbekistan only in limited conditions. The reasonable strategy was found to be the screening for incidental glycemia in all patients with at least one T2D risk factor. It was recommended that patients with incidental glycemia ≥ 7.8 mmol/L should be tested for fasting glycemia.

show abstract

“…Улучшение качества ввода данных в ФРСД является одним из важнейших и приоритетных направлений совершенствования методов оказания медицинской помощи пациентам с СД1 и СД2, учитывая неуклонный рост общих затрат на лечение СД в РФ [20] и необходимость научно обоснованного планирования распределения финансовых средств на реализацию наиболее эффективных стратегий диагностики и лечения СД и его осложнений.…”

Section: заключениеunclassified

The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018)

Antsiferov¹,

Demidov²,

Калашникова³

et al. 2020

Diabetes mellitus

Self Cite

View full text Add to dashboard Cite

BACKGROUND: State Register of Diabetes Mellitus (SRDM) plays an important role in the dynamic analysis of the epidemiological parameters that evaluate the disease itself and its complications, and also helps to analyze the quality of specialized medical care for patients. To solve modern scientific and practical problems, it is important to analyze data not only among the entire population of Russia, but also in large administrative-territorial subjects of the country. AIMS: To Study the dynamics of the main epidemiological indicators (values) among patients with type 1 diabetes mellitus (DM1) and type 2 diabetes mellitus (DM2) living in Moscow for the period from 2013 to 2018 according to the State Register of Diabetes Mellitus (SRDM). MATERIALS AND METHODS: The analysis of Moscow region of the SRDM database was conducted. According to it there were registered 345.1 thousand patients with diabetes by 01.01.2019. RESULTS: During the period from 2013 to 2018 the total number of patients with DM increased up 9.8% (from 314.4 thousand to 345.1 thousand people). DM2 accounts for 94% of the total number of patients. According to SRDM the prevalence of DM1 on 100 thousand population has grown up 6.9% (from 152.2 in 2013 to 162.7 in 2018); DM2 by 9.6% (from 2864.7 in 2013 to 3139.4 in 2018). The incidence of DM1 per 100 thousand people decreased down to 6.4% (from 4.7 in 2013 to 4.4% in 2018); DM2 grew up 4.3% (from 198.1 in 2002, to 206.6 in 2018). Throughout the study period the incidence of DM2 was higher among women, while the opposite trend was observed among women with DM1. The mortality among people with DM1 in 2018 was 1.6 per 100 thousand among adult population (in 2017 it was 1.7); among patients with DM2 the mortality was 56.6 people per 100 thousand among adult population (in 2017 it was 65.6). The first place among the direct causes of death among patients with DM1 and DM2 in 2018 was occupied by cardiovascular diseases (57.5% and 67.9%, respectively), the second place oncological diseases (9.9% and 12.2%). CONCLUSIONS: The results of the epidemiological analysis showed that since 2013 in Moscow there has been an increase in the prevalence of diabetes, against the background of stable indicators of incidence (except for the organizational period of adapting to the new online data entry system of SRDM). The leading causes of death of patients with diabetes are cardiovascular and oncological diseases.

show abstract

Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

Cited by 21 publications

References 18 publications

Modification of Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome

Modification of Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome

Assessing the Effectiveness of Type 2 Diabetes Screening in the Republic of Uzbekistan

The dynamics of the main epidemiological indicators among living in Moscow patients with diabetes mellitus (2013–2018)

Contact Info

Product

Resources

About